As of 2025-09-17, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -3.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 173.93 mil USD. Aclaris's TTM EBITDA according to its financial statements is -55.46 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 10.8x | 7.5x |
| Forward P/E multiples | 8.8x - 17.3x | 12.3x |
| Fair Price | (4.26) - (5.29) | (4.83) |
| Upside | -331.6% - -387.8% | -362.7% |
| Date | EV/EBITDA |
| 2025-09-16 | -3.21 |
| 2025-09-15 | -3.14 |
| 2025-09-12 | -3.35 |
| 2025-09-11 | -3.39 |
| 2025-09-10 | -3.53 |
| 2025-09-09 | -3.70 |
| 2025-09-08 | -3.60 |
| 2025-09-05 | -3.64 |
| 2025-09-04 | -3.59 |
| 2025-09-03 | -3.57 |
| 2025-09-02 | -3.43 |
| 2025-08-29 | -3.31 |
| 2025-08-28 | -3.14 |
| 2025-08-27 | -3.10 |
| 2025-08-26 | -3.08 |
| 2025-08-25 | -3.06 |
| 2025-08-22 | -3.06 |
| 2025-08-21 | -2.96 |
| 2025-08-20 | -3.08 |
| 2025-08-19 | -3.04 |
| 2025-08-18 | -3.16 |
| 2025-08-15 | -3.19 |
| 2025-08-14 | -2.84 |
| 2025-08-13 | -2.86 |
| 2025-08-12 | -2.75 |
| 2025-08-11 | -2.75 |
| 2025-08-08 | -2.73 |
| 2025-08-07 | -2.61 |
| 2025-08-06 | -2.57 |
| 2025-08-05 | -2.57 |
| 2025-08-04 | -2.59 |
| 2025-08-01 | -2.53 |
| 2025-07-31 | -2.53 |
| 2025-07-30 | -2.53 |
| 2025-07-29 | -2.57 |
| 2025-07-28 | -2.82 |
| 2025-07-25 | -2.86 |
| 2025-07-24 | -2.82 |
| 2025-07-23 | -2.82 |
| 2025-07-22 | -2.71 |
| 2025-07-21 | -2.75 |
| 2025-07-18 | -2.69 |
| 2025-07-17 | -2.65 |
| 2025-07-16 | -2.63 |
| 2025-07-15 | -2.51 |
| 2025-07-14 | -2.63 |
| 2025-07-11 | -2.61 |
| 2025-07-10 | -2.65 |
| 2025-07-09 | -2.55 |
| 2025-07-08 | -2.37 |